- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04757116
Eine randomisierte, internationale Studie zur Bewertung der Sicherheit von iTind im Vergleich zu UroLift (MT-08)
Eine prospektive, randomisierte, kontrollierte, multizentrische internationale Post-Market-Studie zur Bewertung der Sicherheit des temporär implantierten Nitinol-Geräts (iTind) im Vergleich zum UroLift®-System bei Patienten mit symptomatischer gutartiger Prostatahyperplasie (BPH)
The study objective is to evaluate the efficacy and safety of the iTind device compared to UroLift.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Both iTind and UroLift are minimally invasive treatment options for relieving lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). The iTind device is a temporary, self-expanding nitinol implant that remains in place for 5 to 7 days to reshape the prostatic urethra through localized ischemic pressure and tissue remodeling. In contrast, the UroLift system involves the permanent placement of transprostatic implants that retract the enlarged lateral lobes of the prostate to widen the urethral lumen.
This study is designed to directly compare the safety and effectiveness of the iTind device versus the UroLift system in treating LUTS due to BPH.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Melanie Bonds, MS
- Telefonnummer: +1-703-851-4615
- E-Mail: Melanie.Bonds@olympus.com
Studienorte
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85054
- Rekrutierung
- Mayo Clinic Arizona
-
Hauptermittler:
- Mitchell Humphreys, MD
-
Kontakt:
- Rev Vilasan Shylaja
- Telefonnummer: 480-574-1466
- E-Mail: VilasanShylaja.Revathy@mayo.edu
-
Tucson, Arizona, Vereinigte Staaten, 85704
- Beendet
- Arizona Urology Specialists
-
-
California
-
Fresno, California, Vereinigte Staaten, 93720
- Rekrutierung
- Urology Associates of Central California
-
Hauptermittler:
- William Schiff, MD
-
Kontakt:
- Joe Vidal
- Telefonnummer: 559-321-2919 559-720-3646
- E-Mail: jvidal@urologyassociates.net
-
Sacramento, California, Vereinigte Staaten, 95823
- Rekrutierung
- Golden State Urology
-
Hauptermittler:
- Prithipal Sethi, MD
-
Kontakt:
- Sehaj Sethi
- Telefonnummer: 308 916-245-8888
- E-Mail: ssethi@goldenstateurology.com
-
-
Illinois
-
Evanston, Illinois, Vereinigte Staaten, 60201
- Beendet
- NorthShore University Health System Research Institute
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70119
- Aktiv, nicht rekrutierend
- Southeast Louisiana Veterans Health Care System
-
-
Minnesota
-
Woodbury, Minnesota, Vereinigte Staaten, 55125
- Zurückgezogen
- Minnesota Urology
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68124
- Rekrutierung
- The Urology Center
-
Hauptermittler:
- Sida Niu, MD
-
Kontakt:
- Amy Nelson
- Telefonnummer: 402-397-7989
- E-Mail: anelson@adultpediatricuro.com
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89121
- Rekrutierung
- Pacific West Urology
-
Kontakt:
- John Dull
- Telefonnummer: 702-321-8045
- E-Mail: john.dull@pacificwesturology.com
-
Hauptermittler:
- Joel Abbott, MD
-
-
New York
-
Syosset, New York, Vereinigte Staaten, 11791
- Rekrutierung
- Feinstein Institutes for Medical Research / Northwell Health
-
Hauptermittler:
- Bilal Chughtai, MD
-
Kontakt:
- Jennifer Polo
- Telefonnummer: 516-628-5926
- E-Mail: jpolo1@northwell.edu
-
-
Tennessee
-
Germantown, Tennessee, Vereinigte Staaten, 38138
- Rekrutierung
- The Conrad Pearson Clinic
-
Hauptermittler:
- Adam Stewart, MD
-
Kontakt:
- Jessica Parks
- Telefonnummer: 901-464-2711
- E-Mail: jessica.parks@conradpearson.com
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78705
- Rekrutierung
- Midtown Urology Associates
-
Hauptermittler:
- Tyler McClintock, MD
-
Kontakt:
- Andrew Barger
- Telefonnummer: 512-451-7935
- E-Mail: APBarger@cimplify.net
-
Houston, Texas, Vereinigte Staaten, 77027
- Rekrutierung
- Houston Metro Urology
-
Kontakt:
- Lena Ellis
- Telefonnummer: 713-634-4405
- E-Mail: lena.ellis@hmutx.com
-
Hauptermittler:
- Mark Sutton, MD
-
San Antonio, Texas, Vereinigte Staaten, 78240
- Rekrutierung
- The Urology Place
-
Hauptermittler:
- Naveen Kella, MD
-
Kontakt:
- Raji Thiruppathiraj
- Telefonnummer: 210-617-3670
- E-Mail: raji@theupi.com
-
-
Virginia
-
Alexandria, Virginia, Vereinigte Staaten, 22311
- Rekrutierung
- Potomac Urology Center
-
Hauptermittler:
- Nilay Gandhi, MD
-
Kontakt:
- Chamin Lim
- Telefonnummer: 423 703-680-2111
- E-Mail: clim@potomacurology.com
-
-
-
-
-
Dunfermline, Vereinigtes Königreich, KY12 0SU
- Rekrutierung
- Queen Margaret Hospital
-
Hauptermittler:
- Feras Al Jaafari, MD
-
Kontakt:
- Keith Boath
- Telefonnummer: 20951 +44-1383-623623
- E-Mail: Keith.boath@nhs.scot
-
London, Vereinigtes Königreich, GU16 7UJ
- Rekrutierung
- Frimley Park Hospital
-
Hauptermittler:
- Neil Barber, MD
-
Kontakt:
- Reynette Baroman
- E-Mail: r.baroman@nhs.net
-
Norwich, Vereinigtes Königreich, NR4 7UY
- Rekrutierung
- Norfolk & Norwich University Hospital
-
Hauptermittler:
- Mark Rochester, MD
-
Kontakt:
- Catherine Rennie
- Telefonnummer: +44-1603 646105
- E-Mail: catherine.rennie@nnuh.nhs.uk
-
-
Middlesex
-
Isleworth, Middlesex, Vereinigtes Königreich, TW7 6AF
- Rekrutierung
- Chelsea and Westminster Hospital
-
Hauptermittler:
- Samuel Bishara, MD
-
Kontakt:
- Farrah Akkouch
- Telefonnummer: +44 (0)20 321 5181
- E-Mail: chelwest.wmh.olympus@nhs.net
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Diagnosis of lower urinary tract symptoms presumed to be secondary to benign prostatic enlargement causing bladder outlet obstruction for which treatment is recommended
- Willing and able to provide informed consent
- Males ≥ 50 years of age or older
- PSA < 4 ng/ml or if the PSA is 4 - 10 ng/ml, prostate cancer must be ruled out to the satisfaction of the Principal Investigator (PI) by local standard of care methods within prior 6 months
- Prostate volume up to 75 cc (inclusive) documented by cross-sectional imaging (TRUS, MRI, etc.). Results from standard of care imaging may be accepted up to 6 months prior to Screening
- International Prostate Symptom Score (IPSS) for urinary symptoms ≥ 13
- Maximum urinary flow rate (Qmax) of ≤ 15 mL/sec and ≥ 5 mL/sec (voided volume must be ≥ 125 mL)
- Willing and able to complete all study visits including questionnaires at baseline and at follow-up visits
Exclusion Criteria:
- History of prostate cancer or suspected, should be ruled out to the satisfaction of the PI by local standard of care methods within prior 6 months
- Confirmed bladder cancer within the last 2 years or currently suspected bladder cancer
- History of acute bacterial prostatitis within the last 2 years
- Median lobe obstruction of the prostate as confirmed by cross-sectional imaging
- PSA value > 10 ng/ml
- Contraindicated for iTind or UroLift as determined by the PI
- Neurogenic bladder and/or sphincter abnormalities due to Parkinson's disease, multiple sclerosis, cerebral vascular accident, diabetes or other neurological disorders that affect bladder function
- Clinically significant bladder diverticulum
- Diagnosed with urethral stricture, meatal stenosis, bladder neck contracture, rectal disease, artificial urinary sphincter, incompetent sphincter, urinary incontinence due to incompetent sphincter
- Prior rectal surgery (other than hemorrhoidectomy) or history of rectal disease treatment if the therapy may potentially cause injury to site (e.g., if a transrectal probe is used), pelvic radiotherapy or radical pelvic surgery, urinary diversion surgery, prostate surgery, balloon dilation, urethral stent implantation, laser prostatectomy, or any other invasive treatment to the prostate, or penile prosthesis if it may prevent insertion of the iTind or UroLift device
- An active urinary tract infection during randomization
- Clinically significant hematuria within the last 3 months or ongoing cystolithiasis
- Prostate volume > 75 cc
- Post-void residual volume (PVR) > 250 mL
- Actively using catheterization or unable to void naturally
- Unable to complete a 2-week washout period for alpha blockers prior to procedure or unable to discontinue 5ARIs or daily use of PDE5 inhibitors by the time of procedure
- Taking anti-platelet or anticoagulants (except low dose aspirin - 81 mg - 100 mg) within the last 7 days prior to procedure
- Known or suspected allergy to nickel, titanium or polyester/polypropylene
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: iTind arm
The iTind is a minimally invasive temporary implant |
The iTind is implemented for 5-7 days |
|
Aktiver Komparator: UroLift
The UroLift is a minimally invasive permanent implant |
UroLift is a minimally invasive procedure where permanent implants are placed in the prostate. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 3 months
Zeitfenster: 3 months
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 3 months |
3 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 12 months
Zeitfenster: 12 month
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 12 months |
12 month
|
|
Incidence of all intraoperative and post-operative adverse events (AEs) (i.e., related to procedure and/or device) through 3 months post-procedure.
Zeitfenster: 3 month
|
Incidence of all intraoperative and post-operative adverse events (AEs) (i.e., related to procedure and/or device) through 3 months post-procedure. |
3 month
|
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 1, 6, 24, and 36 months
Zeitfenster: 1, 6, 24, and 36 months
|
Difference in change of IPSS from baseline between iTind and UroLift groups at 1, 6, 24, and 36 months |
1, 6, 24, and 36 months
|
|
Difference in change of QoL scores (SHIM, MSHQ-EjD, SF-6D) from baseline between iTind and UroLift at 1, 3, 6, 12, 24, and 36 months
Zeitfenster: 1, 3, 6, 12, 24, and 36 months
|
Difference in change of QoL scores (SHIM, MSHQ-EjD, SF-6D) from baseline between iTind and UroLift at 1, 3, 6, 12, 24, and 36 months |
1, 3, 6, 12, 24, and 36 months
|
|
Difference in rate of re-intervention between iTind and UroLift groups at 1, 3, 6, 12, 18, 24, and 36 months
Zeitfenster: 1, 3, 6, 12, 18, 24, and 36 months
|
Difference in rate of re-intervention between iTind and UroLift groups at 1, 3, 6, 12, 18, 24, and 36 months |
1, 3, 6, 12, 18, 24, and 36 months
|
|
Difference in reporting between iTind and UroLift groups at 1, 6, 12, 18, 24, and 36, months •Overall incidence of procedure and/or device related adverse events
Zeitfenster: 1, 6, 12, 18, 24, and 36, months
|
Difference in reporting between iTind and UroLift groups at 1, 6, 12, 18, 24, and 36, months •Overall incidence of procedure and/or device related adverse events |
1, 6, 12, 18, 24, and 36, months
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Neil Barber, MD, Frimley Park Hospital
- Hauptermittler: Bilal Chughtai, MD, Northwell Health
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- MT-08
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .